The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

It's worth noting that Biohaven has just reported that sales of Nurtec ODT came in at $124 million in the first quarter – below analyst projections and the $190 million made in the last quarter ...

Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

The settlement resolves allegations that between March 1, 2020, and September 30, 2022, Biohaven paid kickbacks to providers to present at speaker programs designed to promote Nurtec to Medicaid and ...

Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant) are brand-name oral tablets. They’re both prescribed for treating migraine in adults. This article explains the main similarities and differences ...

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine. CGRP ...

Shares of BHVN opened at $29.87 on Wednesday. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21. The stock has a market cap of $3.02 billion, a PE ratio of -3.19 and a beta of 1.27 ...